Abstract: The invention relates to a long-acting formulation of biopharmaceutical, more specifically an aptamer therapeutics. A branched PEGylated aptamer or a hyaluronic acid (HA) derivative of which degradation in vivo is regulated is linked by the bioconjugation with biopharmaceutical to produce the long-action formulation.

Abstract: The present invention relates to an immunoregulating agent comprising a peptide, a pharmaceutical composition and a method of preventing or treating immune-related disorder such as sever sepsis or acute respiratory distress syndrome (ARDS), and the use of peptide for anti-inflammatory agent, an antibacterial agent, or an inhibiting agent of an immune cell apoptosis.

Abstract: The invention relates to a novel bioconjugation protocol for peptide suitable for in vivo applications. Bioconjugation of the peptide to HA derivative increases its half life in circulation contributing for a high efficacy. More over, conjugate of HA derivative and peptide which is treated with hyaluronidase shows increased bioactivity. And also, in contrast to PEGylation, HA derivative can be conjugated with many numbers of peptide molecules per single HA derivative chain, which enables multiple action of peptide drugs.

Abstract: The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.

Abstract: Provided are a synchronization identifier generating method for synchronizing digital contents and an apparatus for the same. The synchronization identifier generating method includes setting a sampling level that indicates a frequency of sampling digital contents; sampling the digital contents on the basis of the set sampling level; generating a first message digest on the basis of data sampled during the sampling the digital contents; and generating a synchronization identifier including the set sampling level and the first message digest.

Abstract: The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator.

Abstract: A method for preparing amino linker oligonucleotides is provided, wherein an amino protecting group is efficiently removed from the amino linker oligonucleotides protected by the protecting group, and thereby achieving a high yield of the amino linker oligonucleotides.

Abstract: A method of collecting information of interest to a user regarding multimedia content is described. The method may include receiving first content about the information of interest to the user among the multimedia content, collecting metadata of the first content by using a uniform resource identifier (URI) of the first content, extracting at least one first information object including a schema according to a search category from the metadata, and storing the first information object in a first database.

Abstract: The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity.

Abstract: A method of generating relevant information related to multimedia content at a client that reproduces the multimedia content includes accessing a blog service connected to the client, selecting the first content of the multimedia content, for which relevant information is to be generated, by using the blog service, generating the relevant information using a template according to the type of the relevant information generated with respect to the first content, and transmitting the generated relevant information to a server.

Abstract: The present inventors show that a brief exposure to EGF stimulates insulin secretion glucose-independently via a Ca2+ influx- and PLD2-dependent mechanism. Furthermore, the present invention shows that EGF is a novel secretagogue that lowers plasma glucose levels in normal and diabetic mice, suggesting the potential for EGF treatment in diabetes.

Abstract: The present invention relates to method of regulating mammalian target-of-rapamycin (mTOR) based on a novel finding of a regulating mechanism of mTOR by a phospholipase D (PLD), and Ras homolog enriched in brain (Rheb). Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibitin mTOR.

Abstract: The present application describes peptides that stimulate arachidonic acid release in target cells. The application also discloses peptides that cause intracellular calcium release. The application also discloses methods of using the disclosed peptides.

Abstract: Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or neutrophils in vitro; that induce degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; that stimulate extracellular signal regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; or that stimulate Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1.

Abstract: Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or neutrophils in vitro; that induce degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; that stimulate extracellular signal regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; or that stimulate Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1.

Abstract: A method of providing a slide show includes selecting one of a plurality of images in which geographic position information is set, marking a plurality of positions corresponding to the plurality of images on a map based on geographic position information and outputting the map, setting an image search range on the map based on a position on the map, which corresponds to the selected image, and providing the slide show by using images corresponding to positions on the map, which belong to the set image search range.

Abstract: Provided are a method and apparatus for generating a playlist of media content and a method and apparatus for playing media content. The method of generating a playlist of media content includes providing a user interface for setting a playlist while media content is being played and generating a playlist of media content to be played according to playlist settings set through the user interface.

Abstract: The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity.

Abstract: A method and apparatus for synchronizing feed information are provided. A podcasting client includes a synchronization-processing unit which synchronizes first feed information acquired from a connected device with pre-stored second feed information, and a communication interface which transmits feed information of content that is podcast based on the synchronized feed information to the connected device.

Abstract: The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator.